Health & Life Technologies
“The Health category, in addition to therapies, diagnostics and medical devices, also covers sport and well-being and targets research results with strong transfer potential. It is challenged by market demand; and we are carrying out targeted monitoring, issuing Calls for Expressions of Interest, and consulting academic and industrial experts. The “Prostate cancer antisense” project is a novel approach using synthetic therapeutic DNA to block a target expressed in prostate cancer; this project is co-financed by Inserm Transfert.
The sport and well-being sub-category is looking promising in the context of Marseille-Provence being European Capital of Sport in 2017.”
Health & Life Technologies Facilitator
Health & Life Technologies Project Manager
PROJETS DE MATURATION 2015
Atherosclerosis diagnosis: Centre Méditerranéen de Médecine Moléculaire (C3M, Université Nice Sophia Antipolis, Inserm, U1065), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC, Inserm, UMR 1048)
Development of a biomarker to prevent an initial heart attack in populations predisposed to Acute Coronary Syndrome (ACS) before rupture of the atherosclerotic plaque.
ISA method and re-encoding of viruses: Laboratoire Emergence des Pathologies Virales (EPV, Aix-Marseille Université, Inserm, IRD, U190)
New process for obtaining vaccines from attenuated viruses. The maturation program focuses on candidate vaccines for veterinary use, with an assessment of their production yield and their infectiousness.
Pluripotent cell differentiation process: Laboratoire Génétique Médicale et Génomique Fonctionnelle (Aix-Marseille Université, Inserm, UMR_S910)
The maturation program should make it possible to produce predictive models of different types of neuronal cells from human-induced pluripotent stem cells. The aim is to propose non-toxicity tests of drug candidates or to confirm their effectiveness on neurodegenerative human models.
Prostate Cancer Antisens: Centre de Recherche en Cancérologie de Marseille (CRCM, Aix-Marseille Université, CNRS, Inserm, U1098)
The aim of the project is to demonstrate the effectiveness of therapeutic synthetic DNAs that interact with a mRNA encoding for a protein expressed during tumor development. The purpose of this program is to slow down the development of tumors and reduce resistance to hormone treatments and chemotherapies.
M-CSF: Centre d’Immunologie Marseille-Luminy (CIML, Aix-Marseille Université, CNRS, Inserm, U6102)
Preventive and curative treatment designed to strengthen and speed up restoration of the immune system in immunedepressed patients who have received stem cell grafts. This treatment can be used to prevent the development of fungal, viral or bacterial infections that accompany this type of transplant.
Dengue antivirals: Laboratoires Architecture et Fonction des Macromolécules Biologiques (AFMB, Aix-Marseille Université, CNRS, UMR 7257), Émergence des Pathologies Virales (EPV, Aix-Marseille Université, Inserm, UMR_S190)
4 serotypes of the Dengue virus compared to molecules that have been developed, or are under development, by pharmaceutical or biotech companies.